https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT04557098
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma - NCI
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
a studymultiple myelomateclistamabparticipantsrelapsed
https://www.zorginstituutnederland.nl/documenten/2024/07/10/pakketadvies-sluisgeneesmiddel-teclistamab-tecvayli-bij-multipel-myeloom
Advies - niet vergoeden teclistamab (Tecvayli®) voor de behandeling van multipel myeloom |...
Zorginstituut Nederland adviseert om teclistamab (Tecvayli®) niet te vergoeden uit het basispakket van de zorgverzekering. Dit medicijn wordt gebruikt bij de...
de behandelingadviesnietvergoedenteclistamab
https://www.ablesci.com/assist/detail?id=LodJXG
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed...
author correctioninduction treatmentnewly diagnosedteclistamabbased
https://healthtree.org/video/1weHa503fyKEEEtYroNX
Real-World Evidence for Teclistamab in Myeloma | Dr. Rakesh Popat Shares #EHA2025 Insights
Learn from Dr. Rakesh Popat how this bispecific antibody therapy is performing outside of clinical trials.
real world evidenceteclistamabmyelomarakeshpopat
https://www.mayo.edu/research/clinical-trials/cls-20602743?p=1
A Study Comparing JNJ-79635322 And Teclistamab In Participants With Relapsed Or Refractory Multiple...
a studycomparingjnjteclistamabparticipants